Literature DB >> 27261088

Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model.

Yihao Tao1, Lin Li2, Bing Jiang1, Zhou Feng1, Liming Yang1, Jun Tang1, Qianwei Chen1, Jianbo Zhang1, Qiang Tan1, Hua Feng1, Zhi Chen3, Gang Zhu4.   

Abstract

Excessive inflammatory responses are involved in secondary brain injury during germinal matrix hemorrhage (GMH). The process of microglial polarization to the pro-inflammatory M1 or anti-inflammatory M2 phenotypes is considered to occur in a major immunomodulatory manner during brain inflammation. We previously found that cannabinoid receptor-2 (CB2R) stimulation attenuated microglial accumulation and brain injury following experimental GMH. However, whether CB2R has effects on microglial polarization after GMH remains unclear. Herein, we investigated the effects of CB2R stimulation on neuroinflammation after experimental GMH and the potential mechanisms that mediate M1/M2 microglial phenotype regulation. The results indicated that during the GMH acute phase, microglia primarily polarized to the M1 phenotype and induced an overwhelming release of pro-inflammatory cytokines. However, JWH133, a selective CB2R agonist, significantly prevented the pro-inflammatory cytokine release while promoting an M1 to M2 phenotype transformation in microglia, resulting in an increased anti-inflammatory cytokine release. Moreover, in thrombin-induced rat primary microglial cells, JWH133 reduced the pro-inflammatory cytokine levels and M1 phenotype by enhancing the acquisition of the M2 phenotype. Additionally, JWH133 facilitated synthesis of cyclic AMP (cAMP) and its downstream effectors, phosphorylated cAMP-dependent protein kinase (p-PKA) and exchange protein activated by cyclic-AMP 1 (Epac1). The promoting effects of JWH133 on M2 polarization were attenuated with a specific PKA inhibitor but not with an Epac inhibitor, indicating that the cAMP/PKA signaling pathway was involved in the JWH133 effects. This is the first study to propose that promotion of microglial M2 polarization through the cAMP/PKA pathway participates in the CB2R-mediated anti-inflammatory effects after GMH induction. The results will help to further understand the mechanisms that underlie neuroprotection by CB2R in GMH and promote clinical translational research for CB2R agonists.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-inflammation; Cannabinoid receptor-2; Microglial polarization; PKA

Mesh:

Substances:

Year:  2016        PMID: 27261088     DOI: 10.1016/j.bbi.2016.05.020

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  31 in total

1.  Identifying the hub gene and immune infiltration of osteoarthritis by bioinformatical methods.

Authors:  Chengmao Zhao
Journal:  Clin Rheumatol       Date:  2020-08-12       Impact factor: 2.980

2.  Chemerin suppresses neuroinflammation and improves neurological recovery via CaMKK2/AMPK/Nrf2 pathway after germinal matrix hemorrhage in neonatal rats.

Authors:  Yixin Zhang; Ningbo Xu; Yan Ding; Yiting Zhang; Qian Li; Jerry Flores; Mina Haghighiabyaneh; Desislava Doycheva; Jiping Tang; John H Zhang
Journal:  Brain Behav Immun       Date:  2018-03-01       Impact factor: 7.217

3.  The Cannabinoid WIN 55,212-2 Reduces Delayed Neurologic Sequelae After Carbon Monoxide Poisoning by Promoting Microglial M2 Polarization Through ST2 Signaling.

Authors:  Jing-Jing Du; Zhi-Qin Liu; Yue Yan; Jing Xiong; Xiao-Tao Jia; Zheng-Li Di; Jing-Jing Ren
Journal:  J Mol Neurosci       Date:  2019-11-15       Impact factor: 3.444

4.  Cannabinoid Receptor 2 (CB2) Inverse Agonist SMM-189 Induces Expression of Endogenous CB2 and Protein Kinase A That Differentially Modulates the Immune Response and Suppresses Experimental Colitis.

Authors:  Sonia Kiran; Ahmed Rakib; Bob M Moore; Udai P Singh
Journal:  Pharmaceutics       Date:  2022-04-26       Impact factor: 6.525

Review 5.  Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder.

Authors:  Reza Rahimian; Claudia Belliveau; Rebecca Chen; Naguib Mechawar
Journal:  Front Psychiatry       Date:  2022-06-16       Impact factor: 5.435

6.  Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-adrenergic receptor signaling after rat spinal cord injury.

Authors:  Jiandong Gao; Zhihua Sun; Zhaoyang Xiao; Qihang Du; Xinhuan Niu; Gongming Wang; Yu-Wen Chang; Yongtao Sun; Wei Sun; Amity Lin; Jacqueline C Bresnahan; Mervyn Maze; Michael S Beattie; Jonathan Z Pan
Journal:  Br J Anaesth       Date:  2019-10-14       Impact factor: 9.166

Review 7.  Cannabinoid Modulation of the Stressed Hippocampus.

Authors:  Franciele F Scarante; Carla Vila-Verde; Vinícius L Detoni; Nilson C Ferreira-Junior; Francisco S Guimarães; Alline C Campos
Journal:  Front Mol Neurosci       Date:  2017-12-19       Impact factor: 5.639

8.  Endogenous hydrogen sulphide attenuates NLRP3 inflammasome-mediated neuroinflammation by suppressing the P2X7 receptor after intracerebral haemorrhage in rats.

Authors:  Hengli Zhao; Pengyu Pan; Yang Yang; Hongfei Ge; Weixiang Chen; Jie Qu; Jiantao Shi; Gaoyu Cui; Xin Liu; Hua Feng; Yujie Chen
Journal:  J Neuroinflammation       Date:  2017-08-18       Impact factor: 8.322

9.  Cannabinoid receptor 2 deficiency enhances isoflurane-induced spatial cognitive impairment in adult mice by affecting neuroinflammation, neurogenesis and neuroplasticity.

Authors:  Chao Li; Jingpu Shi; Jiaguang Sun; Yuanyuan Shi; Huiqun Jia
Journal:  Exp Ther Med       Date:  2021-06-25       Impact factor: 2.447

10.  Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.

Authors:  Peng Jin; Shuixiang Deng; Prativa Sherchan; Yuhui Cui; Lei Huang; Gaigai Li; Lifei Lian; Shucai Xie; Cameron Lenahan; Zachary D Travis; John H Zhang; Ye Gong; Jiping Tang
Journal:  Neurotherapeutics       Date:  2021-07-09       Impact factor: 6.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.